Understanding KRAS Lung Cancer
In recent years, exciting progress has been made in research and treatment for patients with KRAS mutations, the most prevalent mutation in lung cancer. While doctors have known that KRAS mutations occur in more than 20% of lung cancer patients, they’re now learning how different subtypes behave -- and respond to targeted therapies.
Lurie Cancer Center’s Jyoti Patel, MD, an internationally recognized expert in the treatment of patients with lung cancer, discussed the latest information, advocacy and clinical trials for KRAS lung cancer, in a three-part webinar series hosted by Patient Power.
Watch all the segments in the series and read the transcripts:
- Part 1: What is KRAS Lung Cancer?
- Part 2: How Can KRAS Patients Get Involved and Learn More?
- Part 3: What KRAS Clinical Trials Are Available?